Last edition
News about "Tozorakimab "
AstraZeneca Reports Positive Phase 3 Results for Tozorakimab in COPD
AstraZeneca’s Phase 3 OBERON and TITANIA trials showed that tozorakimab reduced moderate-to-severe COPD exacerbations across broad patient populations, including different blood eosinophil levels and smoking statuses.
Tozorakimab | 10/09/2026 | By News Bureau
AstraZeneca's Tozorakimab Hits Key Phase 3 Goal in COPD Trial
AstraZeneca reports positive Phase III MIRANDA trial results for tozorakimab in COPD, marking its third successful pivotal study and reinforcing the potential of its IL-33-targeting biologic to transform respiratory care.
Tozorakimab | 21/04/2026 | By News Bureau | 170
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy